PT  - JOURNAL ARTICLE
AU  - Bernadette J. Prentice
AU  - Adam Jaffe
AU  - Shihab Hameed
AU  - Charles F. Verge
AU  - Shafagh Waters
AU  - John Widger
TI  - Cystic fibrosis-related diabetes and lung disease: an update
AID  - 10.1183/16000617.0293-2020
DP  - 2021 Mar 31
TA  - European Respiratory Review
PG  - 200293
VI  - 30
IP  - 159
4099  - http://err.ersjournals.com/content/30/159/200293.short
4100  - http://err.ersjournals.com/content/30/159/200293.full
SO  - EUROPEAN RESPIRATORY REVIEW2021 Mar 31; 30
AB  - The development of cystic fibrosis-related diabetes (CFRD) often leads to poorer outcomes in patients with cystic fibrosis including increases in pulmonary exacerbations, poorer lung function and early mortality. This review highlights the many factors contributing to the clinical decline seen in patients diagnosed with CFRD, highlighting the important role of nutrition, the direct effect of hyperglycaemia on the lungs, the immunomodulatory effects of high glucose levels and the potential role of genetic modifiers in CFRD.Cystic fibrosis (CF)-related diabetes remains one of the most important comorbidities for patients with CF because of the impact on lung function and mortality. There are numerous factors in addition to infection that contribute to the negative effects of CF-related diabetes. https://bit.ly/3nSPFW6